» Articles » PMID: 38163206

FDA-approved Heterocyclic Molecules for Cancer Treatment: Synthesis, Dosage, Mechanism of Action and Their Adverse Effect

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Jan 1
PMID 38163206
Authors
Affiliations
Soon will be listed here.
Abstract

As the incorporation of heterocycles increases the physical characteristics and biological activity of pharmacological molecules, heterocyclic scaffolds are commonly discovered as common cores in a wide spectrum of biologically active drugs. In the contemporary context, many heterocycles have arisen, playing vital roles in diverse pharmaceutical compounds that benefit humanity. Over 85 % of FDA-approved medication molecules contain heterocycles, and most importantly, numerous heterocyclic medicinal molecules indicate potential benefits against a range: of malignancies. The unique flexibility and dynamic core scaffold of these compounds have aided anticancer research. These medications are used to treat cancer patients by targeting particular genes, enzymes, and receptors. Aside from the drugs that are now on the market, numerous forms are being researched for their potential anti-cancer activity. Here in this review, we classified some molecules and biologically active heterocycles containing anticancer medicinal moieties approved by the FDA between 2019 and 2021 based on their use in various forms of cancer. We will focus on those that are suitable for cancer treatment, as well as the essential biochemical mechanisms of action, biological targets, synthetic methods, and inherent limiting considerations in their use.

Citing Articles

Inhibition of Kinase Activity and In Vitro Downregulation of the Protein Kinases in Lung Cancer and Cervical Cancer Cell Lines and the Identified Known Anticancer Compounds of .

Sambo T, Mathe E, Shai L, Mapfumari S, Gololo S Plants (Basel). 2025; 14(3).

PMID: 39942957 PMC: 11820244. DOI: 10.3390/plants14030395.


Oxazolo[5,4-]pyrimidines as Anticancer Agents: A Comprehensive Review of the Literature Focusing on SAR Analysis.

Sochacka-Cwikla A, Maczynski M Molecules. 2025; 30(3).

PMID: 39942770 PMC: 11820477. DOI: 10.3390/molecules30030666.


Synthesis and crystal structure of piperidinyl propanenitrile towards the preparation of piperidine based bioactive films for drug delivery applications.

Mohamed-Ezzat R, Hasanin M, Kariuki B, Dacrory S Sci Rep. 2025; 15(1):705.

PMID: 39753604 PMC: 11698915. DOI: 10.1038/s41598-024-81996-6.


Design, synthesis, biological evaluation, kinetic studies and molecular modeling of imidazo-isoxazole derivatives targeting both α-amylase and α-glucosidase inhibitors.

AlRashidi E, Ghannay S, Albadri A, Abid M, Kadri A, Aouadi K Heliyon. 2024; 10(20):e38376.

PMID: 39640664 PMC: 11619978. DOI: 10.1016/j.heliyon.2024.e38376.


Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-]pyrimidine Derivatives for Prostate and Bladder Cancer Treatment.

Massaro M, Ciani R, Grossi G, Cavallaro G, de Melo Barbosa R, Falesiedi M Pharmaceutics. 2024; 16(11).

PMID: 39598551 PMC: 11597611. DOI: 10.3390/pharmaceutics16111428.


References
1.
Begley C, Ellis L . Drug development: Raise standards for preclinical cancer research. Nature. 2012; 483(7391):531-3. DOI: 10.1038/483531a. View

2.
Peerzada M, Hamel E, Bai R, Supuran C, Azam A . Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. Pharmacol Ther. 2021; 225:107860. DOI: 10.1016/j.pharmthera.2021.107860. View

3.
Dhillon S . Ripretinib: First Approval. Drugs. 2020; 80(11):1133-1138. PMC: 7595980. DOI: 10.1007/s40265-020-01348-2. View

4.
Alrooqi M, Khan S, Alhumaydhi F, Asiri S, Alshamrani M, Mashraqi M . A Therapeutic Journey of Pyridine-based Heterocyclic Compounds as Potent Anticancer Agents: A Review (From 2017 to 2021). Anticancer Agents Med Chem. 2022; 22(15):2775-2787. DOI: 10.2174/1871520622666220324102849. View

5.
Markham A . Erdafitinib: First Global Approval. Drugs. 2019; 79(9):1017-1021. DOI: 10.1007/s40265-019-01142-9. View